Besides, UHRF1 overexpression is observed in numerous cancers as is the case with EZH2, which may enable us to apply what is learnt from RB's case to other UHRF1‐overexpressing cancers if UHRF1 inhibitors can be successfully developed. Here, EZH2 is linked to cancer.